T1	Participants 542 577	2437 patients with a history of HSL
T2	Participants 793 921	1443 patients experienced a recurrence and initiated treatment with ME-609 (n = 601), acyclovir (n = 610), or placebo (n = 232).
T3	Participants 1134 1167	patients with ulcerative lesions,
